Background: Pneumococcal vaccination has been reported to have confl icting results on preventing adverse cardiovascular events in a myriad of populations. We therefore investigated the effect of pneumococcal vaccination on preventing subsequent adverse cardiovascular events in a group of high-risk patients; those presenting with an ST-elevation myocardial infarction (STEMI). Methods: Patients undergoing acute percutaneous coronary intervention (PCI) for a STEMI at a single community referral hospital were prospectively entered into American College of Cardiology (ACC) cardiac catheterization/PCI registry. Information regarding pneumococcal vaccination and outcomes relating to recurrent MI and death were obtained from chart abstraction. Results: Four hundred and seventy-three patients underwent PCI for a STEMI from 1/1/2007 to 12/31/2010. The majority of patients were male (64.9%) and Caucasian (99.6%), with a mean age of 63.6 years (±13.8). During a median follow-up of 12.7 months, there were 69 (14.6%) deaths and 22 (4.5%) recurrent MIs. Patients who had received pneumococcal vaccination were at increased risk of mortality (hazard ratio = 2.08; 95% confi dence interval 1.34-3.23; P = 0.001). However, patients who had received pneumococcal vaccination were older, and more likely to have hypertension and diabetes. After correcting for confounders in a multivariate Cox regression model, there was no signifi cant association of pneumococcal vaccination with increased mortality. There was also no signifi cant difference in recurrent MI. Conclusion: Pneumococcal vaccination was not associated with differences in all-cause mortality or recurrent MI, after correcting for major confounding clinical variables. Given the confl icting fi ndings regarding pneumococcal vaccination, a prospective, randomized study will be required to clarify its cardio-protective role, if any.
INTRODUCTION
In spite of major advances in treatment, heart disease remains the number one cause of mortality in the United State. 1 The rise in incidence of acute myocardial infarction (MI) in the winter months is a well-documented phenomenon. 2 Risk of MI and strokes have been reported to increase substantially after a diagnosis of systemic respiratory tract infections. 3, 4 This risk was highest in the fi rst 3 days after diagnosis and decreased thereafter. 3 The same phenomenon, but to a lesser extent, was also noted with urinary tract infections. As plaque rupture and subsequent destabilization leads to the vast majority of acute coronary syndromes (ACS), 5 infl ammation related to an acute infection would be a plausible explanation accounting for increased incidence of MI in the postinfectious period. 6 In the context of infection destabilizing and preceding an ACS, there has been great interest in reducing ACS by preventing respiratory tract infections, either through infl uenza vaccination 7, 8 or prophylactic use of antibiotics. 9, 10 Interestingly pneumococcal vaccination in Ldlr −/− mice reduced extent of atherosclerosis and plasma from these mice given to Ldlr −/− naïve mice transferred the protective benefi t. 11 The benefi t was shown to be attributable to induction of high levels of anti-oxidized low-density lipoprotein-specifi c Immunoglobulin M levels, which were
Original Article cross-reactive with pneumococcal determinants. A clinical association of pneumococcal vaccination with reduction in MI was fi rst shown by Lamontagne et al. 12 Since the initial report, there has been intense debate regarding the coronary benefi ts of pneumococcal vaccination with studies reporting confl icting results. [13] [14] [15] [16] [17] Our own study in patients with suspected ACS revealed a signifi cantly lower 6-month mortality rate in those who had received pneumococcal vaccination with or without influenza vaccine. 18 However, our study had the limitation of being predominantly male with patients suspected of an ACS, of whom only a subset had bona fi de ACS or non-ST-elevation MI (STEMI). In addition, none of the studies targeted highrisk patients such as those presenting with acute STEMI. With this background in mind, our current study explores the association between pneumococcal vaccination and subsequent adverse cardiovascular outcomes in a relatively homogenous population of all patients presenting with a STEMI and undergoing primary coronary intervention at a single, tertiary care referral center.
METHODS
Patients presenting to Westmoreland Regional Hospital of the Excela Health System with a STEMI, eligible for an acute catheterization-based intervention and successfully undergoing the procedure were entered into an American College of Cardiology (ACC)-cath database prospectively. Demographics on the patients and detailed variables such as use of anti-platelet agents and cardiac medications as well as admission parameters and outcomes related to the admission (cardiogenic shock, use of intra-aortic balloon counter-pulsation, death) were all entered into the database prospectively. Pneumococcal vaccination status was determined by chart abstraction from the time of admission related to the STEMI as well as all subsequent admissions. All patients admitted to the hospital are asked routinely about their infl uenza and pneumococcal vaccination status and offered the vaccination if they meet criteria as part of a quality measure set by the hospital. Hence, this information was available on all patients admitted with a STEMI.
Patient's demographics, past medical history, smoking history, physical examination fi ndings, coronary imaging, initial and follow-up laboratory results, and admission and discharge medications were obtained from the ACC/ cath database. The left ventricle ejection fraction was obtained from left ventriculography performed as part of the cardiac catheterization or from echocardiogram (if ventriculography not done). The primary end-point was a combination of all-cause mortality and recurrent MI during follow-up. Mortality data and data regarding recurrent MI was obtained by chart abstraction of hospital admissions subsequent to the STEMI admission. All study protocols were approved by the Institutional Review Board with waiver of informed consent.
Statistical analysis
Patient demographic characteristics were compared between patients who had received pneumococcal vaccination and those who had not received pneumococcal vaccination prior to the index STEMI using Chi-square statistic for categorical variables and the Student's unpaired t-test for continuous variables. A two-tailed P < 0.05 was considered as signifi cant. Kaplan-Meir survival curves were generated for the two groups of patients using recurrent MI, all-cause mortality and combined recurrent MI and death as an outcome variable of interest. Cox regression modeling was performed to assess the effect of receipt of pneumococcal vaccination on these outcomes. Multiple patient demographic and presenting variables were entered into a Cox model in a univariate manner to assess which of these were signifi cant. Univariate variables identifi ed to be signifi cant at a P ≤ 0.10 were entered into a multivariate model Cox regression model along with the addition of receipt of infl uenza and pneumococcal vaccination to assess any associations with adverse outcomes that may remain after correcting for the multiple signifi cant clinical variables identifi ed in the univariate modeling. All analyses were performed using STATA 12.1 (STATA Corp., College Station, Texas, USA).
RESULTS
Four hundred and seventy-three patients presenting with a STEMI and undergoing percutaneous coronary intervention (PCI) from 01/01/2007 to 12/31/2010 were enrolled in the ACC catheterization/PCI registry. The study population was predominantly Caucasian (99.6%) and male (64.9%) with a mean age of 63.6 years (±13.8). Mean follow-up duration was 68.2 (±64.8) weeks. There were a total of 69 (14.6%) deaths, 22 (4.7%) recurrent MI, with fi ve patients presenting with recurrent MI leading to death during the same hospitalization. Hence, there were a total of 86 (18.2%) patients with composite outcome of death or recurrent MI. 6 (1.3%) patients had a cerebrovascular accident during follow-up and 3 (0.6%) had a documented transient ischemic attack. 165 (34.9%) of patients had received pneumococcal vaccination prior to the index MI, with 28 (5.9%) patients receiving it during follow-up. We analyzed the data with just pneumococcal vaccination being received prior to index MI, as well as including the 5.9% of patients that received pneumococcal vaccination after the index MI in a separate analysis. The results, with or without these 5.9% of patients, remained unchanged. Hence, here we present the results with the 5.9% of patients being included as immunized in the analysis.
Not surprisingly patients who had received pneumococcal vaccination had more comorbidity as compared to the non-vaccinated group. Patients who had received pneumococcal vaccination were signifi cantly older, female, with history of congestive heart failure (CHF), diabetes mellitus, hypertension, hyperlipidemia, chronic obstructive pulmonary disease as well as prior coronary artery disease, and strokes (Table 1) , as compared to the non-vaccinated group. However, the non-vaccinated group was more likely to be smokers. There was no difference in peak troponin-I levels or the medications at time of discharge between the two groups (Table 1) .
Patients were more likely to have received influenza vaccination in the season prior to the index MI presentation if they had also received pneumococcal vaccination. There was a signifi cant correlation between the two vaccines (R = 0.61, P < 0.0001), with 82% of patients who had received pneumococcal vaccination also being vaccinated against infl uenza. Similar to pneumococcal vaccination, patients who had received infl uenza vaccination were statistically signifi cantly older, and more likely to have comorbidities such as previous MI, diabetes mellitus, prior stroke and dyslipidemia and less likely to be current smokers (data not shown). This is not surprising as the Center for Disease Control recommendation for pneumococcal vaccination and infl uenza vaccination are very similar.
There were a total 69 deaths in our study, the majority of whom had received the pneumococcal vaccination (22.4% vs. 9.3%, P < 0.001; (Figure 1a) ). There was no difference in the recurrent MI rate (P = 0.462; (Figure 1b) ). There were 86 (18.2%) cases with death or recurrent MI, with higher rates of the combined end-point among patients with pneumococcal vaccination compared to the non-vaccinated ones (P = 0.001; (Figure 1c) ). However, this difference was driven entirely by differences in mortality rate.
We entered various clinical variables into a univariate Cox regression model using a joint outcome variable of allcause mortality and recurrent MI. The univariate analyses identifi ed age >65 yrs, smoking within 1 year, history of stroke, CHF, pulmonary edema on presentation, cardiogenic shock, chronic renal insuffi ciency, body mass index >25, infl uenza, and pneumococcal vaccination parameters to be signifi cantly associated with the outcome ( Congestive heart failure, CVA: Cerebrovascular accident P = 0.001) of all-cause mortality and recurrent MI. These results remained unchanged whether patients, who had received pneumococcal vaccination after the index MI, albeit a minority, were treated as vaccinated or not for the purpose of regression analysis. Receipt of infl uenza vaccination was also associated with higher HR of death or recurrent MI (HR = 1.92; 95% CI: 1.18-3.11; P = 0.009). These results were not surprising given that patients who had received infl uenza vaccination had a signifi cantly higher load of comorbidities than those who had not, very similar to patients who had received pneumococcal vaccination.
To correct for the multiple signifi cant univariate variables identifi ed above, they were all entered into a multivariate Cox regression model along with a receipt of infl uenza or pneumococcal vaccination. After correcting for all the other clinical variables, neither receipt of infl uenza (HR = 1.56; 95% CI = 0.79-3.06; P = 0.200) nor pneumococcal vaccination (HR = 0.83; 95% CI = 0.40-1.72; P = 0.616) was associated with adverse combined outcomes of death or recurrent MI (Table 3) .
DISCUSSION
In our cohort of patients presenting with a STEMI and undergoing primary PCI, receipt of pneumococcal vaccination was not associated with improvements in adverse combined outcomes of all-cause mortality or recurrent MI. In fact, in univariate regression modeling, there was increased risk of adverse outcomes in patients who had received the pneumococcal vaccination. However, patients who had received pneumococcal vaccination were older, with a higher burden of comorbidities. Once these clinical factors were corrected for statistically in a multivariate regression model, patients with pneumococcal vaccination were at no different risk of mortality or recurrent MI as compared to those without receipt of pneumococcal vaccination.
We also looked at infl uenza vaccination status for the season preceding the time of the index hospitalization for STEMI. Patients who had received pneumococcal vaccination were much more likely to have received infl uenza vaccination. This was not surprising as the indications for both vaccines are very similar and healthy behaviors would be expected to run together. Like pneumococcal vaccination, infl uenza vaccine was associated with higher risk of death or recurrent MI in a univariate model, an association that disappeared once pertinent clinical variables were corrected for.
Our fi ndings are in sharp contrast to the study reported by Lamontagne et al. who reported an adjusted odds ratio of 0.53 for MI in patients who had received pneumococcal vaccination as compared to controls. 12 Unlike our study, where the statistically signifi cant differences were driven largely by mortality and not recurrent MI, the study by Lamontagne et al. was not designed to look at mortality differences. It is possible that the controls chosen from the surgical fl oors are likely to be a healthier population than those admitted to medical fl oors with a suspected ACS or found to have had an MI. It is also likely that the immunization status of the control population is an indirect marker of healthy behavior 19 This point is also high-lighted by our own study cohort where patients who had been immunized to pneumococcal vaccination, had a high (82%) incidence of being vaccination against infl uenza as well.
Prior study of veteran population presenting with a suspected ACS/non-ST-elevation MI revealed a decrease in all-cause mortality at 6-month in patients who had received pneumococcal vaccination, with or without the receipt of infl uenza vaccine. 18 The benefi cial effect reported was largely driven again by all-cause mortality and not by differences in rates of recurrent MI. Unlike our study, this was a cohort of patients with "suspected" ACS, many of whom did not have an ACS. Another concerning limitation was an inability to distinguish between in-hospital and discharge medications. Differences in rates of prescription of cardiac medication could confound the results signifi cantly, and account for the benefi cial effect seen as patients likely to seek pneumococcal vaccination are also likely to be a more medically compliant population.
One of the largest, prospective, population-based cohort study from Spain failed to show a benefi cial effect of pneumococcal vaccination in altering the risk of acute MI or death from acute MI. 17 Their fi ndings were similar to the study reported by Tseng et al . that failed to demonstrate a benefi cial effect of pneumococcal vaccination in preventing MI or stroke in men over 45 years of age. 13 Our study fi ndings are in agreement with these. We chose a relatively high-risk group of patients; those presenting with a STEMI and all eligible and undergoing primary PCI. Our study cohort from that standpoint was fairly homogenous as far as cardiac pathology is concerned in that everyone had underlying coronary artery disease and a major presentation of it. Yet we failed to demonstrate a benefi cial effect of pneumococcal vaccination in this highrisk group. On the contrary, patient who had received prior pneumococcal vaccination had higher mortality, a refl ection likely of these patients having signifi cantly more comorbid conditions. Indeed, after correcting for these comorbidities, there was no effect noted of pneumococcal vaccination on all-cause mortality/recurrent MI.
In contrast to our own study, Eurich et al. have reported a 58% reduction in acute coronary events associated with pneumococcal vaccination in patients presenting with community acquired pneumonia within 90 days of their presentation. 16 These results remained unchanged after extensive adjustments for clinical variables as well as propensity score matching. However, the authors did conclude that they still could not completely exclude a "healthy vaccine" effect.
CONCLUSION
In our study, receipt of pneumococcal vaccination in a high-risk population presenting with a STEMI undergoing sicker and yet a more health-conscious population, thus confounding the data in either direction, as well as more likely to receive infl uenza vaccination ("health vaccine"), a prospective, randomized, controlled study will be required to clarify its cardio-protective role, if any, perhaps similar in design to the randomized trial showing benefi t of the infl uenza vaccination. 8 There are several limitations to our study. Our study population is small, almost exclusively Caucasian, and from one tertiary care community referral hospital. We did not have data on cause-specifi c mortality and utilized all-cause mortality as an outcome measure. We also did not have data on the incidence of pneumococcal infections preceding the index STEMI, to explore any causality. Despite these limitations, our study does not support any cardio-protective role for pneumococcal vaccination, and the indications for administration of pneumococcal vaccination should remain unchanged.
